

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 July 2021 (22.07.2021)



(10) International Publication Number
WO 2021/146256 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2021/013200

(22) International Filing Date:
13 January 2021 (13.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/960,663 13 January 2020 (13.01.2020) US
63/070,728 26 August 2020 (26.08.2020) US
63/091,717 14 October 2020 (14.10.2020) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **DENNIS, Mark S.**; c/o Denali Therapeutics
Inc., 161 Oyster Point Blvd., South San Francisco, Cali-
fornia 94080 (US). **GU, Zhenyu**; c/o Denali Therapeutics
Inc., 161 Oyster Point Blvd., South San Francisco, Califor-
nia 94080 (US). **KAROLIS, Mihalios S.**; c/o Denali Ther-
apeutics Inc., 161 Oyster Point Blvd., South San Francis-
co, California 94080 (US). **MAHON, Cathal S.**; c/o Denali
Therapeutics Inc., 161 Oyster Point Blvd., South San Fran-
cisco, California 94080 (US). **MONROE, Kathryn M.**; c/
o Denali Therapeutics Inc., 161 Oyster Point Blvd., South
San Francisco, California 94080 (US). **PARK, Joshua I.**;
c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South
San Francisco, California 94080 (US). **PROROK, Rachel**;
c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South
San Francisco, California 94080 (US). **SILVERMAN,
Adam P.**; c/o Denali Therapeutics Inc., 161 Oyster Point
Blvd., South San Francisco, California 94080 (US). **VAN
LENGERICH, Bettina**; c/o Denali Therapeutics Inc., 161
Oyster Point Blvd., South San Francisco, California 94080
(US).

(74) Agent: **YAO, Zhengzheng** et al.; Kilpatrick Townsend &
Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree
Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2021/146256 A1

(54) Title: ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.